Grace Therapeutics Management
Management criteria checks 0/4
Grace Therapeutics' CEO is Prashant Kohli, appointed in Apr 2023, has a tenure of 1.67 years. total yearly compensation is $987.63K, comprised of 40.5% salary and 59.5% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $76.88K. The average tenure of the management team and the board of directors is 1.6 years and 1.5 years respectively.
Key information
Prashant Kohli
Chief executive officer
US$987.6k
Total compensation
| CEO salary percentage | 40.5% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.6yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Sep 02
We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
Apr 20Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Nov 14We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
May 10Acasti Pharma GAAP EPS of -$0.10
Aug 11Acasti inks deal for Grace Therapeutics, shares surge
May 07Acasti Pharma issues clarification on trading activity
Dec 23Acasti Pharma EPS in-line
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$12m |
| Jun 30 2024 | n/a | n/a | -US$11m |
| Mar 31 2024 | US$988k | US$400k | -US$13m |
| Dec 31 2023 | n/a | n/a | -US$39m |
| Sep 30 2023 | n/a | n/a | -US$40m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | US$512k | US$379k | -US$42m |
| Dec 31 2022 | n/a | n/a | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$17m |
| Jun 30 2022 | n/a | n/a | -US$11m |
| Mar 31 2022 | US$655k | US$141k | -US$10m |
Compensation vs Market: Prashant's total compensation ($USD987.63K) is above average for companies of similar size in the US market ($USD650.00K).
Compensation vs Earnings: Prashant's compensation has increased whilst the company is unprofitable.
CEO
Prashant Kohli (52 yo)
1.7yrs
Tenure
US$987,630
Compensation
Mr. Prashant Kohli was Vice President of Commercial Operations at Grace Therapeutics, Inc. He served as Chief Commercial Officer at Acasti Pharma Inc. since 2022 until April 04, 2023, and serves as its Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$987.63k | 0.21% $ 76.9k | |
| VP of Program Management | 1.6yrs | US$405.75k | 0.11% $ 40.0k | |
| VP of Clinical Operations | 1.6yrs | US$411.30k | 0% $ 0 | |
| VP of Finance and Principal Financial & Accounting Officer | 1.1yrs | no data | no data | |
| Member of Scientific Advisory Board & Chief Medical Officer | 1.6yrs | no data | no data |
1.6yrs
Average Tenure
52yo
Average Age
Experienced Management: GRCE's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.2yrs | US$987.63k | 0.21% $ 76.9k | |
| Member of Scientific Advisory Board & Chief Medical Officer | 2.6yrs | no data | no data | |
| Independent Director | 1.2yrs | US$53.00k | 0.37% $ 136.4k | |
| Independent Director | 1.2yrs | US$57.50k | 0% $ 0 | |
| Independent Chairman | 3.3yrs | US$127.43k | 15.92% $ 5.8m | |
| Director | 1.2yrs | US$44.90k | 3.65% $ 1.3m | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data |
1.5yrs
Average Tenure
56yo
Average Age
Experienced Board: GRCE's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:04 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Grace Therapeutics, Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Douglas Loe | Byron Capital Markets |